1Gunthert U,Stauder R,Maver B,et al.Are CD44 variant isforms involved in human tumor progression? Cancer Surveys,1995,24:19-24.
2Anttila MA,Tammi RH,Tammi MI,et al.High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer.Cancer Res,2000,60:150-155.
3Darai E,Scoazec JY.Expression of cadherins and CD44 proteins in ovarian tumors physiopathology and diagnosis interest.Eur J Obstet Gynecol Reprod Biol,1999,86:131-133.
4Strobel T,Swanson L,Cannistra SA.In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice:a novel role for CD44 in the process of peritoneal implantation.Cancer Res,1997,57:1228～1232.
5Saegusa M,Machida D,Hashimura M,et al.CD44 expression in benign, premalignant,and malignant ovarian neoplasms:relation to tumour development and progression.J Pathol,1999,189:326-337.
6Chhieng DC,Yee H,Cangiarella JF,et al.Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells in pelvic washings.Cancer,2000,90:299-306.
7Darai E,Bringuier AF,Walker-Combrouze F,et al.Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary.Hum Reprod,1998,13:2831-2835.
8Taylor DD,Gercel-Taylor C,Gall SA.Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies.J Soc Gynecol Investig,1996,3:289-294.
9Schroder W,Rudlowski C,Biesterfeld S,et al.Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.Anticancer Res,1999,19:3901-3906.
10Sancho-Torres I,Mesonero C,Miller-Watelet JL,et al.Clear cell carcinoma of ovary:characterization of its CD44 isoform repertoire.Gynecol Onocol,2000,79:187-195.
3Simon I, Zhuo S, Corral L, et al. CD44 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer [J]. Cancer ges, 2006, 66(3): 1570-1575.
4Simon I, Liu Y, Krall K L, et al. Evaluation of the novel serum markers CD44, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer[J]. Gynecol Oncol, 2007, 106(1):112-118.
5Bast R C Jr. Status of tumor markers in ovarian cancer screening[J]. J Clin Oncol, 2003, 21(10 Suppl):200-205.
6Piver M S, Baker T R, Driscoll D L. Lack of substantial five year disease-free survival by primary aggressive surgery and cisplatinbased chemotherapy or by salvage intraperitoneal cisplatin-based ehemotherapy[J].Eur J Gynaecol Oncol, 1990, 11(4):243-250.
7Saegusa M, Machida D,Hashimura M, et aI.CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to turnout development and progression[J]. J Pathol,1999,189(3):326- 337.
